Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1342-1347

  Gentilini, Oreste ^a   Botteri, E ^a   Rotmensz, N ^a   Intra, M ^a   Gatti, G ^a   Silva, L ^a   Peradze, N ^a   Sahium, R C ^a   Gil, L B ^a   Luini, A ^a   Veronesi, P ^a   Galimberti, V ^a   Gandini, S ^a   Goldhirsh, A ^a   Veronesi, U ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Hormone receptor; Mastectomy; Radiotherapy; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION;

EID: 34548159217     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm182     Document Type: Article

References (9)

1. Early Breast Cancer Triallsts' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival an overview of the randomised trials. Lancet. 2005;366:2106-2106.
2. Recht A, Edge SB, Solin LJ et al. Postmastectomy radiotherapy: guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1539-1569.
3. Marubi E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester: Wiley 1995; 331.
4. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
5. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
6. Strom EA, Woodwaed WA, Kati A et al. Int J Radiat Oncol Biol Phys 2005; 63: 1508-1513.
7. Piccart-Gebhart W, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-postive breast cancer. N Engl J Med 2005; 353: 1659-1672.
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive bread cancer. N Engl J Med 2005; 353: 1673-1684.
9. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-postive bread cancer: A randomised controlled trial. Lancet 2007; 369: 29-36